CD8A and neoplasm: They proved that olaparib, a Poly(ADP-ribose) polymerase inhibitor (PARPi), could enhance the anti-tumor immune response of EGFRvIII-specific CAR-T cells as well as the recruitment of CD8+ T cells in mouse breast cancer models.